USA / 2023 Sees Second Highest FDA Approval Count in 30 Years
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Address: 7500 Security Boulevard, Baltimore, MD 21244
Tel: -3376
Web: http://www.cms.gov/
The Medicare and Medicaid programs were signed into law on July 30, 1965. President LBJ is pictured at the signing ceremony in Independence, Missouri at the Truman Library. Former President Truman is seated beside him. LBJ held the ceremony there to honor President Truman’s leadership on health insurance, which he first proposed in 1945. You can read LBJ’s speech at the signing ceremony and listen to his taped conversations relating to CMS programs. Key speeches and press conference excerpts from other President’s are also available. See the links in the Downloads section below.
The most significant legislative change to Medicare–called the Medicare Modernization Act or MMA–was signed into law by another President from Texas, George W. Bush, on December 8, 2003. This historic legislation adds an outpatient prescription drug benefit to Medicare and makes many other important changes. You can read his speech at the signing ceremony and see pictures of the event at the White House web site. See the links in the Downloads and Related Links Outside CMS sections below.
Oral histories of former Secretaries, Administrators, Members of Congress and other important players in the history of CMS programs are available as well as more oral histories and other CMS related-materials on the SSA web page. See the links in the Downloads and Related Links Outside CMS sections below.
Since 1965, a number of changes have been made to CMS programs. A more detailed listing of those changes is at CMS milestones. Moreover, the agencies charged with implementing the programs have changed as well. See agency history for more information about Medicare’s early days in Social Security, Medicaid’s early days in the Social and Rehabilitative Services Administration, and why they were joined together into one agency in 1977. Learn why CMS headquarters is located in Baltimore County, Maryland and how it was almost moved to the City of Baltimore. See the links in the Downloads and Related Links Outside CMS sections below.
The Centers for Medicare & Medicaid Services (CMS) ten Field offices reorganized in February 2007 moving from a geography-based structure to a Consortia structure based on the Agency’s key lines of business: Medicare health plans, Medicare financial management, Medicare fee for service operations, Medicaid and children’s health, survey & certification and quality improvement. The intent of the new structure is to improve performance through uniform issue management, consistent communication and leadership focused on achieving the Agency’s strategic action plan. Over the past year, the Field has made progress in these areas and more.
Medicare, Medicaid/CHIP, Medicare-Medicaid Coordination, Insurance Oversight, Innovation Center, Regulations and Guidance Research, Statistics, Data and Systems, Outreach and Education
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Cardiff Advisory’s David H. Crean outlines the positive atmosphere and sentiment observed at JPM 2024, the annual healthcare financing conference held near San Francisco’s Union Square. Dr. Crean picks up…
Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the…
As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.…
Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma…
As the US Inflation Reduction Act (IRA) starts to become a reality, and both big pharma and biotech companies brace themselves for its more widespread impact, BIO names Washington fixture,…
The US Food and Drug Administration has increasingly recognized the importance of diversity and representation in clinical trials over the past few decades. This evolution reflects growing awareness across medicine…
AI is the buzzword du jour across all industries, but what is needed for it to truly make a difference in clinical trials? Writing in December 2023’s DIA Global Forum…
Eli Lilly has turned its numbers around and become the world’s most valuable pharma company, thanks to its type 2 diabetes and off-label use obesity drug tirzeptide, which generated no…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this…
Francesco Lanucara of PharmaLex, writing in the November 2023 edition of the DIA’s Global Forum magazine takes a look at how new guidance from the US FDA aims to tackle…
See our Cookie Privacy Policy Here